These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 23410046)

  • 1. Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer.
    Fu L; Guo W; Liu B; Sun L; Bi Z; Zhu L; Wang X; Liu B; Xie Q; Li K
    Biomarkers; 2013 Mar; 18(2):126-35. PubMed ID: 23410046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer.
    Sheu CC; Chang MY; Chang HC; Tsai JR; Lin SR; Chang SJ; Hwang JJ; Huang MS; Chong IW
    Oncology; 2006; 70(3):203-11. PubMed ID: 16809939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer.
    Gao HF; Li AN; Yang JJ; Chen ZH; Xie Z; Zhang XC; Su J; Lou NN; Yan HH; Han JF; Wu YL
    Clin Lung Cancer; 2017 Jan; 18(1):85-91. PubMed ID: 27461774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin 8 and 18 fragments measured in serum and their relation to survival in patients with non-small cell lung cancer.
    Bergqvist M; Brattström D; Hesselius P; Wiklund B; Silen A; Wagenius G; Brodin O
    Anticancer Res; 1999; 19(3A):1833-6. PubMed ID: 10470123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
    Yang JJ; Chen HJ; Yan HH; Zhang XC; Zhou Q; Su J; Wang Z; Xu CR; Huang YS; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Jiang BY; Dong S; Wu YL
    Lung Cancer; 2013 Jan; 79(1):33-9. PubMed ID: 23079155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form.
    Copin MC; Lesaffre M; Berbon M; Doublet L; Leroy C; Tresch E; Porte H; Vicogne J; B Cortot A; Dansin E; Tulasne D
    Lung Cancer; 2016 Nov; 101():59-67. PubMed ID: 27794409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
    Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
    Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of serum MET in non-small-cell lung cancer and its clinical significance.
    Li D; Li F; Wu Y; Zhou D; Chen H
    Clin Biochem; 2015 Feb; 48(3):110-4. PubMed ID: 25489726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High NUAK1 expression correlates with poor prognosis and involved in NSCLC cells migration and invasion.
    Chen P; Li K; Liang Y; Li L; Zhu X
    Exp Lung Res; 2013 Feb; 39(1):9-17. PubMed ID: 23215946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
    Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
    Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
    Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
    Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of consistency of detecting c-MET gene amplification in peripheral blood and tumor tissue of nonsmall cell lung cancer patients.
    Chen D; Xu C; Wu J; Zhang Y; Fang M
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C63-7. PubMed ID: 26323927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
    Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
    Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Level of cytokeratin-19 in serum of patients with non small cell lung cancer].
    Cynowska B; Słomiński JM; Wyrwiński J
    Pneumonol Alergol Pol; 1995; 63(11-12):615-20. PubMed ID: 8616476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
    Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.